GH Research (GHRS)
(Delayed Data from NSDQ)
$11.92 USD
-0.41 (-3.33%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $12.17 +0.25 (2.10%) 7:58 PM ET
3-Hold of 5 3
C Value D Growth B Momentum D VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
GHRS 11.92 -0.41(-3.33%)
Will GHRS be a Portfolio Killer in August?
Zacks Investment Research is releasing its prediction for GHRS based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for GHRS
Recent Price Trend in GH Research (GHRS) is Your Friend, Here's Why
Wall Street Analysts Predict a 166.89% Upside in GH Research (GHRS): Here's What You Should Know
GHRS: What are Zacks experts saying now?
Zacks Private Portfolio Services
How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%
Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?
New Strong Buy Stocks for October 25th
Other News for GHRS
Buy Rating Affirmed for GH Research Amid Positive GH001 Trial Progress and Unique Treatment Potential
GH Research PLC Shareholders Approve Board Resolutions
GH Research Engages Investors at Upcoming Conferences
Largest Clinical-Stage Biotech Drug Stocks Declined 6%
Largest Clinical-Stage BioTech Drug Stocks Declined 6%